Walleye Capital LLC Cuts Holdings in Evolus, Inc. $EOLS

Walleye Capital LLC reduced its position in Evolus, Inc. (NASDAQ:EOLS) by 86.8% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 39,498 shares of the company’s stock after selling 259,450 shares during the period. Walleye Capital LLC’s holdings in Evolus were worth $475,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. AlphaQuest LLC purchased a new position in shares of Evolus in the 1st quarter worth $39,000. IFP Advisors Inc raised its position in shares of Evolus by 99.0% in the 1st quarter. IFP Advisors Inc now owns 9,427 shares of the company’s stock worth $113,000 after buying an additional 4,691 shares during the period. Rafferty Asset Management LLC purchased a new position in shares of Evolus in the 4th quarter worth $115,000. Man Group plc purchased a new position in shares of Evolus in the 4th quarter worth $121,000. Finally, Freestone Grove Partners LP acquired a new stake in Evolus in the 4th quarter valued at $140,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on EOLS shares. Wall Street Zen cut Evolus from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Needham & Company LLC reaffirmed a “hold” rating and issued a $22.00 target price on shares of Evolus in a research report on Wednesday, August 6th. BTIG Research decreased their target price on Evolus from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Finally, HC Wainwright decreased their target price on Evolus from $27.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Evolus has a consensus rating of “Moderate Buy” and a consensus price target of $21.25.

Insiders Place Their Bets

In other Evolus news, Director Albert G. White III bought 20,000 shares of the stock in a transaction dated Monday, June 9th. The stock was bought at an average cost of $9.45 per share, for a total transaction of $189,000.00. Following the completion of the purchase, the director directly owned 50,378 shares of the company’s stock, valued at approximately $476,072.10. The trade was a 65.84% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider David Moatazedi sold 16,582 shares of the firm’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $9.89, for a total value of $163,995.98. Following the sale, the insider owned 364,927 shares of the company’s stock, valued at $3,609,128.03. This represents a 4.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 133,627 shares of company stock valued at $1,325,764 over the last ninety days. Insiders own 6.10% of the company’s stock.

Evolus Stock Down 1.7%

Shares of Evolus stock opened at $7.50 on Wednesday. The business has a 50-day moving average of $8.36 and a 200-day moving average of $10.31. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.27 and a quick ratio of 1.86. The company has a market capitalization of $485.10 million, a PE ratio of -7.65 and a beta of 1.07. Evolus, Inc. has a 1-year low of $5.71 and a 1-year high of $17.82.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.